Humacyte Inc (NASDAQ: HUMA) on Monday, plunged -9.92% from the previous trading day, before settling in for the closing price of $1.31. Within the past 52 weeks, HUMA’s price has moved between $1.09 and $6.77.
Healthcare Sector giant saw their annual sales surged by 42.43% over the last five years. The company achieved an average annual earnings per share of 76.74%. With a float of $158.23 million, this company’s outstanding shares have now reached $158.84 million.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 15.62%, while institutional ownership is 24.69%. The most recent insider transaction that took place on Aug 19 ’25, was worth 1,793,000. In this transaction Director of this company sold 1,100,000 shares at a rate of $1.63, taking the stock ownership to the 591,685 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Director sold 549,360 for $1.83, making the entire transaction worth $1,005,329. This insider now owns 1,691,685 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.21 earnings per share (EPS) for the period topping the consensus outlook (set at -0.25) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 51.26% during the next five years compared to 42.43% growth over the previous five years of trading.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 0.90 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 140.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Analysing the last 5-days average volume posted by the [Humacyte Inc, HUMA], we can find that recorded value of 3.81 million was lower than the volume posted last year of 4.32 million. As of the previous 9 days, the stock’s Stochastic %D was 53.24%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 5.40%, which indicates a significant increase from 4.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0762 in the past 14 days, which was lower than the 0.1316 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4645, while its 200-day Moving Average is $1.9167. Now, the first resistance to watch is $1.2633. This is followed by the second major resistance level at $1.3467. The third major resistance level sits at $1.3933. If the price goes on to break the first support level at $1.1333, it is likely to go to the next support level at $1.0867. Now, if the price goes above the second support level, the third support stands at $1.0033.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 220.98 million based on 187,271K outstanding shares. Right now, sales total 0 K and income totals -148,700 K. The company made 750 K in profit during its latest quarter, and -17,510 K in sales during its previous quarter.
